Bay Area/ San Francisco/ Science, Tech & Medicine

Redwood City's Galvanize Therapeutics Lands $130M to Push Cancer Device Platform

AI Assisted Icon
Published on November 16, 2026
Redwood City's Galvanize Therapeutics Lands $130M to Push Cancer Device Platform3200 Bridge Pkwy. — Galvanize Therapeutics Headquarters
Google Street View

A Redwood City medical device company that builds tools for ablating soft tissue in cancer and chronic lung disease patients has closed an oversubscribed $130 million Series D financing round. Galvanize Therapeutics announced the deal on Monday, saying the new capital will fuel commercial growth and further development of its pulsed electric field, or PEF, technology.

The round was led by HealthQuest Capital, according to the company's own announcement distributed via PR Newswire. Olympus Innovation Ventures and Braidwell LP joined as new investors, while Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company and T. Rowe Price Associates, Inc. also participated in the round, per the same release.

As part of the deal, Garheng Kong — founder and managing partner of HealthQuest Capital — will join Galvanize's board of directors. Kong said the company has “a differentiated PEF platform with potential to advance interventional oncology and pulmonology,” the release states. HealthQuest Capital, which the company describes as having roughly $2 billion in committed capital, focuses on commercial prospects that improve patient outcomes and healthcare delivery efficiency, investing across medical technologies, diagnostics, digital health and innovative services, according to the announcement.

Where the Money Is Headed

Galvanize describes itself as a commercial-stage company pioneering PEF ablation technologies for oncology and chronic disease. Per company statements, proceeds from the financing will support continued commercial expansion of its Aliya platform, investment in clinical evidence generation, advancement of its RheOx therapy for chronic bronchitis, and development of next-generation PEF products and platforms.

Doug Godshall, chairman and chief executive officer of Galvanize Therapeutics, said the financing “marks an important inflection point” and positions the company “to accelerate growth and expand PEF's impact,” according to the same announcement. The Redwood City company is currently commercializing its Aliya PEF platform in the United States.

A Newly Cleared Generator and Growing Procedure Count

Galvanize also touted the FDA clearance and commercial launch of its next-generation Aliya EX Generator. The underlying device, Aliya EX, serves as the next-generation generator for the Aliya PEF System and delivers high-voltage, short-duration electrical energy intended to induce non-thermal regulated cell death during surgical soft-tissue ablation, the company says.

That device received FDA 510(k) clearance for soft-tissue ablation in May 2026, as reported by Endovascular Today. Galvanize announced the completion of the first commercial procedures using the Aliya EX system in August, with cases performed through both percutaneous and endoscopic delivery, according to the outlet.

By the time of this week's financing announcement, Galvanize said it had surpassed 4,000 Aliya PEF procedures performed and had enrolled more than 300 patients in its PROPEL registry — figures reported by the company itself. Galvanize also said the scientific literature on PEF now includes more than 40 peer-reviewed publications. The company notes that preclinical and early clinical data suggest Aliya PEF may promote antigen release that could activate the immune system, though it states that effectiveness for inducing an immune response resulting in patient benefit has not been established.

Regulatory Status and Prior Fundraising

Galvanize states that the Aliya PEF System is 510(k) cleared in the United States for surgical ablation of soft tissue and is not currently commercially available in other geographies. The company describes the device as intended to serve as a tool for surgical ablation of soft tissues, not to treat, cure, prevent or mitigate any specific disease or condition, and says it does not promote off-label use of its products. RheOx, meanwhile, remains an investigational device in the United States, limited by federal law to investigational use, according to the company.

Monday's raise follows an oversubscribed $100 million Series C financing that Galvanize announced via PR Newswire in a September 2025 announcement, which was led by Sofinnova Partners. That earlier round was earmarked to expand the company's commercial footprint and advance clinical and development activities tied to Aliya PEF in solid tumors and RheOx therapy for chronic bronchitis — largely the same priorities the company says now guide its latest round, just over a year later.